Schering to globalize clinical trial management
Schering-Plough plans to globalize its clinical trial operations as part of its action agenda initiated in 2003 which seeks to transform the company into a high-performance competitor. Schering expects its Global Clinical Harmonization program will ensure better planning, prioritization, consistency and, as a result, improve efficiencies. One change will see the integration of Phase IV studies under the same roof as earlier development areas. Schering announced that it entered the "turnaround" phase of its action agenda late last year (1"The Pink Sheet" Nov. 7, 2005, p. 18). The globalization of clinical trial activities is not expected to result in head-count reductions...
You may also be interested in...
The solution to the "innovation threat" facing big pharma lies in making deals outside the company, Schering-Plough CEO Fred Hassan said during an R&D update Nov. 1
In this week's podcast episode of Five Must-Know Things, hear about issues surrounding the proposed IP waiver for coronavirus vaccines, a trial delay for Novavax’s COVID-19 vaccine, an ICER review of multiple myeloma drugs and Galapagos’ efforts to refocus its R&D pipeline.
Private Company Edition: Perceptive/Xontogeny, Abingworth, Kizoo and Droia closed venture capital funds. New biopharma VC financings also include a $105m series C round for Elpiscience and $92m for newly launched Interline.